Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929473 | 0.98 | ALDH1A1 (0.81) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL4578093 | 0.96 | ALDH1A1 (0.70) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL19606960 | 0.86 | ALDH1A1 (0.75) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL8034106 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TDP1SMN1; SMN2TSHRHTT | |
| SCHEMBL16731669 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TDP1SMN1; SMN2TSHRHTT | |
| SCHEMBL4579797 | 0.83 | ALDH1A1 (0.77) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL4578424 | 0.82 | SMN1; SMN2 (0.82) | ALDH1A1SMN1; SMN2TSHRHTTKDM4E | |
| SCHEMBL6687442 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL4578879 | 0.82 | SIGMAR1 (0.55) | ALDH1A1TDP1SMN1; SMN2HTTSIGMAR1 | |
| SCHEMBL4283848 | 0.82 | ALDH1A1 (0.81) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | claimed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | claimed |
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | ALDH1A1 3502/4885TDP1 637/4885SMN1; SMN2 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.